recomBead EBV
against Epstein-Barr virus in human serum or plasma
Mikrogen recomBead EBV tests are quantitative immunoassays, using recombinantly produced antigens, for the detection of human antibodies against diagnostically relevant EBV antigens. They allow differentiation between initial infection and past infection or exclusion of Epstein-Barr virus infection.
Please note: Available for sale in Europe only; details available on request.
Products
Advantages
- Reliable screening by recombinant antigens:
| EBV antigen groups | Abbreviation | Recombinant antigen | IgG | IgM |
| Immediate early antigen | IEA | BZLF1 | yes | yes |
| Early antigen | EA | p54, p138 | yes | yes |
| Virus capsid/structural antigen | VCA | p23 | yes | no |
| p18 | yes | yes | ||
| Nuclear antigen | EBNA-1 | p72 | yes | no |
- Reliable detection of past infections due to very high EBNA-1 specificity
- Reliable detection of acute infections due to very high sensitivity of early antigens
- Informative EBV diagnostics: simultaneous, separate detection of all relevant EBV antigens allows classification into early and late phase EBV infection
- Ideally suited for high sample throughput
- Fully automated processing, software-based evaluation (recomQuant) and connection to the laboratory information system possible
Safe and reliable
Validity check by integrated controls (incubation, conjugate and negative control)
Flexible and compatible
Combination of all Mikrogen recomBead immunoassays possible on one plate - uniform processing and interchangeable reagents
High Standard
CE marking: Our recomBead EBV tests meet the high requirements of the EC Directive 98/79/EC for in vitro diagnostic medical devices